Oral Expectorant Global Market Research Insights with Upcoming Trends Segmentation, Opportunities and Forecast to 2033 | Bayer AG, Sanofi S.A., Novartis AG, Merck KGaA, Viatris Inc.

"The new report published by The Business Research Company, titled Oral Expectorant Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the oral expectorant market size has grown steadily in recent years. It will grow from $3.99 billion in 2023 to $4.18 billion in 2024 at a compound annual growth rate (CAGR) of 4.6%. The oral expectorant market size is expected to see steady growth in the next few years. It will grow to $5.03 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=16496&type=smp

Respiratory Illnesses Propel Growth In The Oral Expectorant Market
The rise in respiratory illnesses is expected to propel the growth of the oral expectorant market going forward. Respiratory illnesses refer to diseases and conditions that affect the respiratory system, including the lungs, airways, and other structures involved in breathing. The number of respiratory illness cases occurs due to air pollution, smoking, respiratory infections, and a rise in chronic conditions such as asthma and chronic obstructive pulmonary disease (COPD). Oral expectorants alleviate symptoms and improve respiratory health for individuals with respiratory illnesses. They also help in clearing mucus, ease breathing, and support overall recovery and well-being. For instance, in May 2024, according to the data published by the National Center for Health Statistics (NCHS), a U.S.-based health statistics agency, the prevalence of current asthma among adults aged 18 and over in the United States increased from 8.4% in 2021 to 8.7% in 2022. Additionally, the incidence of asthma episodes in the past 12 months for adults in the same age group rose from 3.3% in 2021 to 3.7% in 2022. Furthermore, in September 2022, according to the article published by The Lancet, a UK-based book and periodic data publishing organization, 11,255 new cases of respiratory syncytial virus (RSV) that causes respiratory illness were recorded in the 2021 summer, which is 9.50% more compared to 10,280 cases in winter 2020-21. Therefore, an increasing number of corporate travelers is driving the oral expectorant market.

Innovative Formulations In The Oral Expectorant Market
Major companies operating in the oral expectorant market are incorporating the use of clean ingredients, such as organic blueberry flavor, to cater to health-conscious consumers and meet rising demand for natural products. An organic blueberry-flavored expectorant is a medicinal syrup designed to help clear mucus from the respiratory tract, enhanced with natural blueberry flavoring to improve taste and appeal. For instance, in November 2022, Genexa Inc., a US-based clean medicine company, launched a new cough and chest congestion medicine for adults, offering consumers a clean and practical choice for the cold and flu season. The medicine has a natural blueberry flavor, making it a more palatable option for consumers. This new product is the first maximum-strength cough suppressant and expectorant from Genexa, designed to control cough, relieve chest congestion, and help thin and loosen mucus. It replaces the artificial, inactive ingredients category leaders use with a clean alternative. The launch aims to provide consumers with better options for cold and flu season and beyond, addressing concerns about artificial ingredients in medicines.

The oral expectorant market covered in this report is segmented -
1) By Drug Type: Secretion Enhancer, Mucolytics
2) By Dosage Form: Oral Solids, Oral Liquids, Inhalants
3) By Medication: Prescription drugs, Over The Counter Drugs
4) By Distribution Channel: Hospital Pharmacy, Retail Store And Drug Store, Online Pharmacies

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=16496&type=discount

Major companies operating in the oral expectorant market are Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories Ltd, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline (GSK) plc, Merck KGaA, Reckitt Benckiser Group PLC, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca plc , Aurobindo Pharma, Cipla Inc., Dr. Reddy's Laboratories, Hikma Pharmaceuticals PLC, C.H. Boehringer Sohn AG And Co. KG , Lupin Pharmaceuticals, Taro Pharmaceutical Industries Ltd., Perrigo Company plc, Biocon India Private Limited, Cadila Healthcare Ltd., Wockhardt Ltd, Genexa Inc.

Contents of the report:
1. Executive Summary
2. Oral Expectorant Market Report Structure
3. Oral Expectorant Market Trends And Strategies
4. Oral Expectorant Market - Macro Economic Scenario
5. Oral Expectorant Market Size And Growth
…..
27. Oral Expectorant Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.